Remission of Ulcerative Colitis after Appendectomy: A Case Report

Noh, Chee Ho; Cheung, Dae Young; Kim, Tae Ho; Jun, Eun Jung; Lee, In Kyu; Kim, Sang Hyun; Cho, Se Hyun; Park, Soo Heon; Han, Ji Yoon; Kim, Jae Kwang

doi:10.4166/kjg.2010.56.3.201

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28-303339 There have been several case reports 3339 including one by Okazaki et al describing a case of mild UC proctitis “cured” by appendectomy after 3 years of follow up. 33 The largest case series by Bolin et al .…”

Section: Discussionmentioning

confidence: 99%

Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis

Parian

Limketkai

Koh

et al. 2016

Gut

View full text Add to dashboard Cite

Objectives Early appendectomy is inversely associated with the development of ulcerative colitis (UC). However, the impact of appendectomy on the clinical course of UC is controversial, generally favoring a milder disease course. We aim to describe the effect appendectomy has on the disease course of UC with focus on the timing of appendectomy in relation to UC diagnosis. Design Using the National Institute of Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium database of UC patients, the risk of colectomy was compared between patients who did and did not undergo appendectomy. In addition, we performed a meta-analysis of studies which examined the association between appendectomy and colectomy. Results 2980 UC patients were initially included. 111 (4.4%) UC patients had an appendectomy; of which 63 were performed prior to UC diagnosis, and 48 after diagnosis. In multivariable analysis, appendectomy performed at any time was an independent risk factor for colectomy (odds ratio [OR] 1.9, 95% confidence interval [CI] 1.1 – 3.1), with appendectomy performed after UC diagnosis most strongly associated with colectomy (OR: 2.2; 95% CI 1.1 – 4.5). An updated meta-analysis showed appendectomy performed either prior to or after UC diagnosis had no effect on colectomy rates. Conclusions Appendectomy performed at any time in relation to UC diagnosis was not associated with a decrease in severity of disease. In fact, appendectomy after UC diagnosis may be associated with a higher risk of colectomy. These findings question the proposed use of appendectomy as treatment for UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis

Parian

Limketkai

Koh

et al. 2016

Gut

View full text Add to dashboard Cite

show abstract

“…A study of IBD patients in Australia confirmed that appendectomy before diagnosis delays disease onset of both UC and CD and results in fewer flare-ups in the case of UC when compared with patients without prior appendectomy [107]. A case report from Korea also confirmed that a patient with UC experienced a more extended period of remission after appendectomy [108]. However, the therapeutic relationship between CD and appendectomy remains inconclusive.…”

Section: Appendectomymentioning

confidence: 97%

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

Yeshi

Ruscher

Hunter

et al. 2020

JCM

112

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition and immune responses, and various environmental factors. Despite many treatment options, there is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term treatment options have resulted in a substantial economic burden to the healthcare system worldwide. Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies excluding their biosimilars approved by the US Food and Drug Administration for induction and maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently available drugs, especially biologics, is the main challenge in IBD management. Natural products have significant potential as therapeutic agents with an increasing role in health care. Given that natural products display great structural diversity and are relatively easy to modify chemically, they represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the pathology, currently available treatment options for IBD and associated challenges, and the roles played by natural products in health care. It discusses these natural products within the current biodiscovery research agenda, including the applications of drug discovery techniques and the search for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.

show abstract

Animal Models of Inflammatory Bowel Disease for Drug Discovery

Mizoguchi

Andoh

2013

Animal Models for the Study of Human Disease

View full text Add to dashboard Cite

Remission of Ulcerative Colitis after Appendectomy: A Case Report

Cited by 4 publications

References 16 publications

Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis

Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

Animal Models of Inflammatory Bowel Disease for Drug Discovery

Contact Info

Product

Resources

About